New report explores traditional, specialty therapy trend impact to employers

March 27, 2026 – vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) Vertex; combination of deutivacaftor (a CFTR potentiator) and tezacaftor/vanzacaftor (CFTR correctors); expanded indication is based...

The Fall 2025 Prime Therapeutics Report delivers a comprehensive look at the evolving oncology landscape—from rising cancer rates in younger populations to the expanding role of...

Cover image for The evolution of GLP-1s Developing a holistic, individualized strategy to capitalize on opportunities and outcomes Prime Therapeutics /the-evolution-of-glp-1s About Prime...